Synopsis: Shares of the specialty chemicals company remained under pressure despite reporting strong quarterly earnings, as investors closely tracked management’s unchanged full-year growth outlook and awaited stronger forward-looking triggers.
The shares of this mid cap company majorly engaged in manufacturers of specialty chemicals which includes Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities and many more were in focus after the company posted its Q1 FY27 result.
With the market capitalization of Rs. 27,145 Crores, the shares of Acutaas Chemicals Ltd reached an intraday low of Rs. 3209 per share falling upto 8 percent from its previous day close of Rs. 3459 per share and is trading at a P/E of 76.2 whereas industry P/E stands at 33.6.
Q1 FY27 Result
- YoY analysis: Revenue from operations has increased from Rs. 207 Crores in Q1 FY26 to Rs. 330 Crores in Q1 FY27, up 59 percent. Operating profit has increased from Rs. 51 Crores to Rs. 113 Crores, up 121 percent and net profit has increased from Rs.44 Crores to Rs. 75 Crores, up 70 percent
- QoQ analysis: Revenue from operations has decreased from Rs. 433 Crores in Q4 FY26 to Rs. 330 Crores in Q1 FY27, down 23 percent. Operating profit has decreased from Rs. 184 Crores to Rs. 113 Crores, down 38 percent and net profit has decreased from Rs. 134 Crores to Rs. 75 Crores, down 44 percent.
Why the stock fell despite strong result
Despite having delivered a good set of Q1 FY27 results that showed significant growth in terms of revenues, profits, and margins, the share price fell on account of the management sticking to the FY27 revenue growth forecast of 25%.
Management had given indications that they would be willing to reconsider an upward revision if the performance of their business turned out better than anticipated during the previous quarter. Hence, some analysts could view the unchanged forecast as a factor that lacked sufficient near-term catalyst, although the firm has never explicitly cited this as the cause for the fall in its share price.
About the Company
Acutaas Chemicals Limited manufactures specialty chemicals across pharmaceuticals, semiconductors, battery materials, personal care, agrochemicals, and fine chemicals. The company focuses heavily on the research-based manufacturing of premium pharmaceutical intermediates used in regulated APIs, generic APIs, and New Chemical Entities (NCEs), while actively expanding into high-value applications for emerging technologies and next-generation electronics.
In its Q1 FY27 business highlights, Acutaas reported strong growth momentum in its CDMO segment and robust growth in its core Advanced Intermediate business within Pharma Intermediates. Meanwhile, its Specialty Chemicals segment saw strong performance in BFC, though overall gains were partially offset by muted growth in commodity chemicals.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
